This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landuzzi, L. Articles by Lollini, P.-L. Search for Related Content PubMed PubMed Citation Articles by Landuzzi, L. Articles by Lollini, P.-L.

(American Journal of Pathology. 2000;157:2123-2131.)
© 2000 American Society for Investigative Pathology

Regular Articles

The Metastatic Ability of Ewing’s Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit

Lorena Landuzzi^*, Carla De Giovanni^*, Giordano Nicoletti^*, Ilaria Rossi^*, Cinzia Ricci^*, Annalisa Astolfi^*, Luciano Scopece^*, Katia Scotlandi^§, Massimo Serra^§, Gian Paolo Bagnara, Patrizia Nanni and Pier-Luigi Lollini^*

From the Department of Experimental Pathology,^*
Section of Cancer Research; the Institute of Histology and General Embryology; and the Interdepartmental Cancer Research Center "G. Prodi",
University of Bologna; and the National Cancer Institute, Genoa, Biotechnology Satellite Unit;
the Laboratory of Oncologic Research,^§
Rizzoli Institute; Bologna, Italy

Ewing’s sarcoma is a primitive highly malignant tumor of bone and soft tissues usually metastasizing to bone, bone marrow, and lung. Growth factor receptors and their ligands may be involved in its growth and dissemination. We analyzed the expression of c-kit and its ligand stem cell factor (SCF) in a panel of six Ewing’s sarcoma cell lines. All cell lines exhibited substantial levels of surface c-kit expression, and five of six displayed transmembrane SCF on the cell surface. Expression of c-kit was down-modulated in all lines by exposure to exogenous SCF. The SCF treatment was able to confer to cells a growth advantage in vitro, due both to an increase in cell proliferation and to a reduction in the apoptotic rate. When used in the lower compartment of a migration chamber, SCF acted as a strong chemoattractant for Ewing’s sarcoma cells. The pretreatment of cells with SCF reduced their chemotactic response to SCF. In athymic nude mice, Ewing’s sarcoma cells injected intravenously metastasized to the lung and to a variety of extrapulmonary sites, including bone and bone marrow. Metastatic sites resembled those observed in Ewing’s sarcoma patients and corresponded to SCF-rich microenvironments. The in vitro pretreatment of cells with SCF strongly reduced the metastatic ability of Ewing’s sarcoma cells, both to the lung and to extrapulmonary sites. This could be dependent on the down-modulation of c-kit expression observed in SCF-pretreated cells, leading to a reduced sensitivity to the chemotactic and proliferative actions of SCF. Our results indicate that the response to SCF mediated by c-kit may be involved in growth, migration, and metastatic ability of Ewing’s sarcoma cells.

This article has been cited by other articles:

				A. S. Martins, J. L. Ordonez, A. Garcia-Sanchez, D. Herrero, V. Sevillano, D. Osuna, C. Mackintosh, G. Caballero, A. P. Otero, C. Poremba, et al. A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and In vivo Study Cancer Res., August 1, 2008; 68(15): 6260 - 6270. [Abstract] [Full Text] [PDF]

				E. Hendershot Treatment Approaches for Metastatic Ewing's Sarcoma: A Review of the Literature Journal of Pediatric Oncology Nursing, November 1, 2005; 22(6): 339 - 352. [Abstract] [PDF]

				A. J. K. Williamson, B. C. Dibling, J. R. Boyne, P. Selby, and S. A. Burchill Basic Fibroblast Growth Factor-induced Cell Death Is Effected through Sustained Activation of p38MAPK and Up-regulation of the Death Receptor p75NTR J. Biol. Chem., November 12, 2004; 279(46): 47912 - 47928. [Abstract] [Full Text] [PDF]

				S. Croci, L. Landuzzi, A. Astolfi, G. Nicoletti, A. Rosolen, F. Sartori, M. Y. Follo, N. Oliver, C. De Giovanni, P. Nanni, et al. Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells Cancer Res., March 1, 2004; 64(5): 1730 - 1736. [Abstract] [Full Text] [PDF]

				I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761. [Abstract] [Full Text] [PDF]

				A. Madani, K. Kemmer, C. Sweeney, C. Corless, T. Ulbright, M. Heinrich, and L. Einhorn Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors Ann. Onc., June 1, 2003; 14(6): 873 - 880. [Abstract] [Full Text] [PDF]

				B. J. Druker Taking Aim at Ewing's Sarcoma: Is KIT a Target and Will Imatinib Work? J Natl Cancer Inst, November 20, 2002; 94(22): 1660 - 1661. [Full Text] [PDF]

				M. S. Merchant, C.-W. Woo, C. L. Mackall, and C. J. Thiele Potential Use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo Activity J Natl Cancer Inst, November 20, 2002; 94(22): 1673 - 1679. [Abstract] [Full Text] [PDF]